Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » GNVC

 - UBBFriend: Email this page to someone!    
Author Topic: GNVC
TruthLiesWithin
Member


Rate Member
Icon 1 posted      Profile for TruthLiesWithin     Send New Private Message       Edit/Delete Post   Reply With Quote 
Just hopped out of CTIC and got in to GNVC.

GNVC has a phase 3 test going, further along than anything CTIC has.

Ctic 800 mill shares

Gnvc 88 million per yahoo.
Best bet is GNVC

Posts: 793 | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
Newbie13
Member


Rate Member
Icon 1 posted      Profile for Newbie13     Send New Private Message       Edit/Delete Post   Reply With Quote 
Hmmm.. I was looking at this also. Just got out of CTIC at 1.92 was thinking if it goes under 1.50 I was going to buy it up again.
GNVC is a looker though! Great volume today

Posts: 108 | From: Connecticut | Registered: Jun 2009  |  IP: Logged | Report this post to a Moderator
TruthLiesWithin
Member


Rate Member
Icon 1 posted      Profile for TruthLiesWithin     Send New Private Message       Edit/Delete Post   Reply With Quote 
Looks ok, waiting for some breakout type news, got some good swings going though.
Posts: 793 | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line DevelopmentLast update: 8/25/2009 7:25:00 AMGAITHERSBURG, Md., Aug 25, 2009 /PRNewswire-FirstCall via COMTEX/ -- GenVec, Inc. (GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology. Funds from this grant, valued at approximately $2.5 million over three years, will be used to support the development of novel cell lines capable of producing vaccine vectors based on different human serotype groups and encoding inhibitory antigens. "This important grant will support work to advance our cell line technology and enhance GenVec's ability to discover and develop new adenovector-based vaccines and therapeutics," said Dr. Doug Brough, GenVec's Executive Director of Vector Sciences. About GenVec GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at and in the company's various filings with the Securities and Exchange Commission. Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at . These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements. SOURCE GenVec, Inc. Copyright (C) 2009 PR Newswire. All rights reserved
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
jdiddy
Member


Member Rated:
4
Icon 1 posted      Profile for jdiddy     Send New Private Message       Edit/Delete Post   Reply With Quote 
still holding here, this one will go big one day

--------------------
If your not on the edge of ur seat, sell it!
Everything posted is my opinion!

Posts: 992 | From: H-town | Registered: Nov 2006  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
I can't believe it's not over $1.00 today - it got there pre-market last month on a much smaller grant. 50 K or 500K or something.
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
jdiddy
Member


Member Rated:
4
Icon 1 posted      Profile for jdiddy     Send New Private Message       Edit/Delete Post   Reply With Quote 
FMD Vaccine Development
US - The Department of Homeland Security, Science and Technology Directorate, intends to award a contract on a sole-source basis to continue developing and retool production of cell lines and master seeds for foot and mouth disease vaccine.


The authority for this sole source award is FAR 6.302-1 - there is only one source that can provide these services and products to DHS. The contract will be awarded to Genvec, Inc. of Gaithersburg, Maryland. Genvec is the only entity capable of performing these services because it created and owns the intellectually property associated with cell lines and master seeds upon which the vaccine will be based.

--------------------
If your not on the edge of ur seat, sell it!
Everything posted is my opinion!

Posts: 992 | From: H-town | Registered: Nov 2006  |  IP: Logged | Report this post to a Moderator
Dagny
Member


Rate Member
Icon 1 posted      Profile for Dagny     Send New Private Message       Edit/Delete Post   Reply With Quote 
I am with you guys, I'm going to try and get in.
What's the bottom on this today I wonder? Put in order for .79, sounds like a deal to me, This one is a winner imo.

--------------------
Dagny

Posts: 271 | From: Arkansas | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
Dagny did you get in? We're still dropping because of all the negative news today, but it will recover tomorrow or Monday....imo.
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
Dagny
Member


Rate Member
Icon 1 posted      Profile for Dagny     Send New Private Message       Edit/Delete Post   Reply With Quote 
I put in a buy order but it never got filled. Still looking at it. Did great on Bonu!!Sold * 1.13. Bought some SOLM on news, but didn't make or lose any money yet.

--------------------
Dagny

Posts: 271 | From: Arkansas | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
I was taken out of BONU for 4200 at $1.03 and actually got $1.04 for 800 shares on a $1.03 limit order - so it must have been FLYING. I said $1.03 by lunch and I was taken out at 11am!

I made $3,150 on it and was only in less than a week at .43 - Funny (but NOT) I had a buy in yesterday for another 2500 at .70 and CANCELED it at about 3pm to try and buy something else. Didn't get it - BUT BONU dropped to .68 before closing at .73 - so I would have made another $625 and ALMOST woould be recovered from by Eddie Bauer and BHWF losses. Imagine that - I've had 2 doubles and a double 'n a half-er, and I'm still down big over the years - but I've made more in the past 2 months than the past 6 years!

I wish I didn't change my sell down from $1.29 the other day - I put a new order in to buy 8000 at .80 - but it may not drop that low for a bit -This COULD be a $10 stock THIS year, imho. But who knows.....

Good luck!

Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
TruthLiesWithin
Member


Rate Member
Icon 1 posted      Profile for TruthLiesWithin     Send New Private Message       Edit/Delete Post   Reply With Quote 
I am still holding this one, it seems steady enough to do so, or even flip a little.
Posts: 793 | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
GNVC down to .73 today - been steadily dropping for 2 weeks or so.

BONU dropped as low as $1.76 after hitting $3.50 yesterday. But it was 30 cents last week!

Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
Got up to .86 today on no news.. Huge volume.

From Ya hoo thread:

GenVec, Inc. (GNVC) - Quote Info Search : in GenVec, Inc. (GNVC)Messages < Newer Topic | Older Topic >
Heere is the news: 15-Sep-09 02:38 pm I will give you the link later if you don't have one already.

SAME fund that bought 8% of CVM at 45c b4 CVM move just bought 8% of GNVC...gnvc at same govt meetin as CVM

coincidence?

Bam bought 8m shares of GNVC 2 weeks ago....LOVING GNVC now

-------------------
ROSTER:
http://www.csr.nih.gov/Roster_proto/meeting_roster.asp?stdate=9/8/2009&enddate=9 /8/2009&grcode=13&srg=IMMG&SRGDISPLAY=IMM-G&agsqnum=220994
--------------------------------------------------------------------------------

Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
THIS sure wasn't the news we were hoping for. Anyone think it will even matter, since they have 6 months to get over $1 and we may be there by 10am today?? :-)

GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
Sep. 16, 2009 (PR Newswire) --

GAITHERSBURG, Md., Sept. 16 /PRNewswire-FirstCall/ -- On September 15, 2009, GenVec, Inc. (Nasdaq: GNVC) received a notice from The NASDAQ Stock Market stating that the minimum bid price of the Company's common stock was below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with Marketplace Rule 5450(a)(5). The notification letter has no effect at this time on the listing of the Company's common stock on The NASDAQ Global Market. GenVec's common stock will continue to trade on The NASDAQ Global Market under the symbol GNVC.


(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )


The notification letter states that GenVec will be afforded 180 calendar days, or until March 15, 2010, to regain compliance with the minimum closing bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days. NASDAQ may, in its discretion, require the Company's common stock to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.


If the Company does not regain compliance by March 15, 2010, NASDAQ will provide written notification to the Company that the Company's common stock will be delisted. At that time, the Company may appeal NASDAQ's delisting determination to a NASDAQ Listing Qualifications Panel. Alternatively, the Company could apply to transfer its common stock to The NASDAQ Capital Market if it satisfies all of the requirements, other than the minimum bid price requirement, for initial listing on The NASDAQ Capital Market set forth in Marketplace Rule 5505. If the Company were to elect to apply for such transfer and if it satisfies the applicable requirements and its application is approved, the Company would have an additional 180 days to regain compliance with the minimum bid price rule while listed on The NASDAQ Capital Market.


The Company intends to actively monitor the bid price for its common stock between now and March 15, 2010, and will consider available options to resolve the deficiency and regain compliance with the NASDAQ minimum bid price requirement.


About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.


Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding the Company's ability to comply with applicable listing standards, the ability to transfer to The NASDAQ Capital Market and actions by NASDAQ, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.


INVESTOR CONTACT: MEDIA CONTACT:GenVec, Inc. Tiberend Strategic Advisors, Inc.Danielle DiPirro Andrew Mielach(301) 944-1877 (212) 827-0020ddipirro*genvec.com amielach*tiberendstrategicadvisors.com


SOURCE GenVec, Inc.


Source: PR Newswire (September 16, 2009 - 8:30 AM EDT)

News by QuoteMedia
www.quotemedia.com

Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
TruthLiesWithin
Member


Rate Member
Icon 1 posted      Profile for TruthLiesWithin     Send New Private Message       Edit/Delete Post   Reply With Quote 
I sold last week.

Putting my chips in SOEN and a few other solar companies.

I still see lots of under a buck Nasdaq's

Posts: 793 | Registered: Aug 2004  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share